Literature DB >> 2245171

Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

H Sigurdsson1, B Baldetorp, A Borg, M Dalberg, M Fernö, D Killander, H Olsson, J Ranstam.   

Abstract

The use of continuous prognostic variables is clinically impractical, and arbitrarily chosen cut-off points can result in a loss of prognostic information. Here we report findings from a study of primary breast cancer, showing how the prognostic value of the fraction of cells in the S-phase of the cell cycle (SPF), as measured by flow cytometry, can be affected by the SPF cut-off level(s) adopted. It was possible to evaluate the SPF in 566 (94%) of 603 consecutive cases where fresh frozen specimens were available in a tumour bank at our department. Clinically, all patients were without distant spread at the time of diagnosis, and the median duration of follow-up was 4 years. Using different survival end-points and chi 2 values for each cut-off level, two optimal cut-off points, at the 7% and 12% levels, were consistently obtained for the SPF. Furthermore, both disease-free survival and the relative risk of recurrence exhibited a non-linear relationship with SPF values; the curves implied that the prognosis was better among patients with SPF values about 2-5% than in patients with lower SPF values (parabolic shape), though the relationship with higher SPF values approached linearity. The non-linearity of the curves is incompatible with the general use of the median SPF as a prognostic cut-off value. An alternative procedure might be to use two cut-off levels, one to distinguish patients with the lowest SPF values (i.e. within the parabolic survival curve) from those with higher values (i.e. with a survival curve approaching linearity), the other to distinguish between patients with intermediate SPF values and those with high values (i.e. within the almost linear part of the survival curve). The 7% and 12% obtained here would be suitable for this purpose. We conclude that prognostic information can be gained by dividing the SPF into three prognostic categories (less than 7.0%, 7.0-11.9% and greater than or equal to 12%), instead of using the median SPF level.

Entities:  

Mesh:

Year:  1990        PMID: 2245171      PMCID: PMC1971535          DOI: 10.1038/bjc.1990.380

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  The long-term prognostic significance of the thymidine labelling index in breast cancer.

Authors:  M Tubiana; M H Pejovic; N Chavaudra; G Contesso; E P Malaise
Journal:  Int J Cancer       Date:  1984-04-15       Impact factor: 7.396

2.  CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors.

Authors:  U Abel; J Berger; H Wiebelt
Journal:  Methods Inf Med       Date:  1984-07       Impact factor: 2.176

3.  Picogram per cell determination of DNA by flow cytofluorometry.

Authors:  G M Lee; J T Thornthwaite; E M Rasch
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

4.  Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations.

Authors:  J S Meyer; M D Coplin
Journal:  Am J Clin Pathol       Date:  1988-05       Impact factor: 2.493

5.  Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; M Lehtinen; T Koivula
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

6.  A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers.

Authors:  R W McDivitt; K R Stone; R B Craig; J O Palmer; J S Meyer; W C Bauer
Journal:  Cancer       Date:  1986-01-15       Impact factor: 6.860

7.  Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Di Fronzo; A Morabito; P Valagussa; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

8.  Prediction of early course of breast carcinoma by thymidine labeling.

Authors:  J S Meyer; E Friedman; M M McCrate; W C Bauer
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

9.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

10.  Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level.

Authors:  A Courdi; M Héry; P Chauvel; J Gioanni; M Namer; F Demard
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

View more
  11 in total

1.  Why do so many prognostic factors fail to pan out?

Authors:  S G Hilsenbeck; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Changes in proliferation activity and relative distributions of lymphoid cell subpopulations in congenitally athymic nu/nu mice and Lurcher mice with spontaneous olivopontocerebellar degeneration.

Authors:  M Cervinková; P Mandáková; P Síma
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

4.  Bayesian random threshold estimation in a Cox proportional hazards cure model.

Authors:  Lili Zhao; Dai Feng; Emily L Bellile; Jeremy M G Taylor
Journal:  Stat Med       Date:  2013-09-06       Impact factor: 2.373

5.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

6.  Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.

Authors:  H Kreipe; P Alm; H Olsson; M Hauberg; L Fischer; R Parwaresch
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

7.  Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.

Authors:  M Fernö; B Baldetorp; P O Bendahl; A Borg; S B Ewers; H Olsson; S Rydén; H Sigurdsson; D Killander
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 8.  DNA Cytometry Consensus Conference. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.

Authors:  D W Hedley; G M Clark; C J Cornelisse; D Killander; T Kute; D Merkel
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

9.  Categorising continuous variables.

Authors:  D G Altman
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.

Authors:  A Borg; J Lennerstrand; M Stenmark-Askmalm; M Fernö; A Brisfors; A Ohrvik; O Stål; D Killander; D Lane; J Brundell
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.